A randomized controlled study in 2018 found that granulocyte colony-stimulating factor with or without hemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events as compared with routine treatment [21]. This evidence concerns the gene CSF3 and fibrosis.